Fertility Preservation Before Gonadotoxic Therapy: A Comprehensive Clinical Review

Abstract

Gonadotoxic therapies, including chemotherapy and radiation, threaten reproductive potential in patients of reproductive age facing cancer or certain autoimmune diseases. This review synthesizes current evidence and clinical guidance on fertility preservation strategies prior to initiating gonadotoxic treatments. It explores epidemiology, pathophysiology, risk stratification, clinical assessment, diagnostic protocols, and the spectrum of fertility preservation modalities, with an emphasis on recent advances and guideline-based recommendations. Clinicians will gain a nuanced understanding of mechanisms of gonadotoxicity, patient selection, and practical considerations for timely intervention, supporting shared decision-making and optimal patient outcomes.

Introduction

The increasing survival rates in patients undergoing gonadotoxic therapies, such as chemotherapy and radiation, have shifted the focus toward long-term quality of life issues, particularly fertility preservation. As the incidence of cancer in young adults and children rises, so does the need for effective fertility preservation strategies. The American Society of Clinical Oncology (ASCO) and European Society for Medical Oncology (ESMO) emphasize discussing infertility risk and preservation options with all patients of reproductive potential before starting gonadotoxic therapy. This review provides an in-depth examination of the epidemiology, mechanisms, clinical assessment, and recent advances in fertility preservation, tailored for healthcare professionals involved in the care of these patients.

Epidemiology / Disease Burden

Cancer remains a leading cause of morbidity in reproductive-aged individuals, with an estimated 10% of new diagnoses occurring in patients under 45 years old. Advances in cancer therapy have increased 5-year survival rates, resulting in over 400,000 childhood and adolescent cancer survivors in the United States alone. However, up to 80% of survivors exposed to alkylating agents or pelvic irradiation experience significant gonadal dysfunction and infertility. The disease burden is amplified by psychosocial distress related to loss of reproductive potential, highlighting the necessity of integrating fertility preservation into cancer care pathways.

Pathophysiology

Gonadotoxic agents exert their effects via direct DNA damage, apoptosis, and vascular compromise within the gonads. In females, chemotherapy and radiation can deplete the primordial follicle pool, disrupt hormone synthesis, and induce ovarian fibrosis, culminating in premature ovarian insufficiency (POI). In males, spermatogonial stem cells are highly susceptible to cytotoxic injury, leading to oligospermia or azoospermia. Radiation doses as low as 2 Gy can impair spermatogenesis, while higher doses (>20 Gy) often cause irreversible testicular failure. The extent of gonadal damage is drug-, dose-, and age-dependent, necessitating individualized risk assessment.

Risk Factors

Key risk factors for infertility following gonadotoxic therapy include young age at treatment, cumulative and type of cytotoxic agent (notably alkylating agents), radiation field and dose, baseline ovarian reserve or semen parameters, and underlying disease state. Females over 35 years face heightened risk due to reduced ovarian reserve. In males, prepubertal status confers some protection, though high-dose regimens can still cause permanent damage. Recognizing these risk factors is crucial for patient counseling and timely referral.

Clinical Features

Most patients are asymptomatic prior to therapy. Post-treatment, women may present with menstrual irregularities, amenorrhea, or symptoms of hypoestrogenism, while men may experience reduced libido, erectile dysfunction, or infertility. Clinical assessment should include detailed reproductive history, menstrual pattern, pubertal development, and prior exposures. In survivors, signs of premature gonadal failure necessitate endocrine evaluation and fertility assessment.

Diagnosis

Baseline fertility assessment includes measurement of serum follicle-stimulating hormone (FSH), luteinizing hormone (LH), anti-Müllerian hormone (AMH), and estradiol in females, and FSH, LH, and testosterone in males. Antral follicle count (AFC) by transvaginal ultrasound provides additional assessment of ovarian reserve. Semen analysis is the cornerstone of male fertility evaluation. Genetic counseling may be indicated for certain malignancies. Timely diagnosis facilitates prompt implementation of fertility preservation measures.

Treatment & Management

Fertility preservation should be discussed before starting gonadotoxic therapy. In females, options include embryo cryopreservation (the gold standard), oocyte cryopreservation, ovarian tissue cryopreservation, and, in select cases, ovarian transposition (oophoropexy). Embryo and oocyte cryopreservation require ovarian stimulation, typically with gonadotropins; random-start protocols permit rapid initiation. Ovarian tissue cryopreservation is the only option for prepubertal girls or when urgent therapy precludes stimulation. In males, sperm cryopreservation remains the standard, with testicular sperm extraction considered for azoospermic or prepubertal patients. Hormonal suppression with GnRH analogs may provide some ovarian protection, though evidence is mixed and not sufficient as a sole strategy. Multidisciplinary collaboration ensures optimal care and consideration of psychosocial factors.

Recent Advances / Emerging Therapies

Vitrification techniques have improved oocyte and embryo survival rates post-thaw, increasing the success of cryopreservation. Ovarian tissue transplantation has resulted in over 200 live births globally. In vitro maturation (IVM) and artificial ovary development represent promising avenues, potentially offering fertility preservation without the need for ovarian stimulation. Spermatogonial stem cell transplantation and testicular tissue cryopreservation are under investigation for prepubertal boys. Molecular profiling of gonadal tissue may allow improved prediction of individual risk and tailored preservation strategies in the near future.

Guideline Recommendations

ASCO, ESMO, and the American Society for Reproductive Medicine (ASRM) recommend that all patients of reproductive age receiving gonadotoxic therapy be counseled on potential infertility and referred to reproductive specialists promptly. Embryo and oocyte cryopreservation are established options, while ovarian tissue cryopreservation is considered experimental but increasingly utilized. Sperm cryopreservation is standard for postpubertal males. Informed consent, including discussion of risks, benefits, and success rates, is critical. Coordination between oncology, reproductive medicine, and psychosocial services is strongly advised.

Conclusion

Fertility preservation prior to gonadotoxic therapy is a crucial aspect of comprehensive cancer and chronic disease care. Early risk assessment, patient-centered counseling, and timely intervention are pivotal in optimizing reproductive outcomes. Advances in cryopreservation techniques and emerging therapies continue to expand available options. Adherence to guideline recommendations and multidisciplinary collaboration remain essential to ensure that patients retain the possibility of future biological parenthood, thereby improving survivorship and quality of life.